RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Meeting With FDA Can Increase the Probability of Product Approval

Meeting With FDA Can Increase the Probability of Product Approval

Posted 01 October 2010

Formal meetings with reviewers at the US Food and Drug Administration (FDA) are among the most important and useful resources available to sponsors of medicinal products seeking marketing approval in the US. These meetings provide an opportunity for companies to discuss product development strategies with the regulators and clarify interpretations of the regulations. In 1997, under the Prescription Drug User Fee Act (PDUFA), the US Congress mandated FDA meetings with applicants to guide and assist them in planning and submitting appropriate information in all the steps leading to marketing a medicinal product.1 Since then, FDA personnel have participated in hundreds of meetings each year covering all kinds of applications. Although this article uses drug terminology, the information applies to biological products, medical devices, generics, over-the-counter drugs and all other products regulated by FDA.

 

© 2022 Regulatory Affairs Professionals Society.